Fidelity Investments’s Perspective Therapeutics CATX Stock Holding History
Bought
Maintained
Sold
Other funds holding CATX
TCM
CC
APM
AAA
SSC
Fidelity Investments's CATX Position: Q2 2026 in Review
Fidelity Investments increased its Perspective Therapeutics (CATX) stake by 4.3% in Q2 2026, buying an estimated $51.4K and bringing the position to 327,253 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2969.
Fidelity Investments first reported a position in CATX in Q3 2019 and has held it in 15 quarters since. The position peaked at $73.5M in Q3 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.
- Fidelity Investments held 327,253 shares of Perspective Therapeutics worth $1.12M as of Q2 2026.
- Fidelity Investments bought 13,595 Perspective Therapeutics shares in Q2 2026, an estimated $51.4K.
- Perspective Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2969 holding.
- Fidelity Investments first reported a position in Perspective Therapeutics in Q3 2019 and has held it in 15 quarters since.
- Fidelity Investments's Perspective Therapeutics position peaked at $73.5M in Q3 2024.
- 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.